Sofia Bogiatzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sofia Bogiatzi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Yatim
Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
1 shared publicationAmélie Osio
Pathology Department Saint‐Louis Hospital Paris France
1 shared publicationAngela Estenaga
Pathology Department Saint‐Louis Hospital Paris France
1 shared publicationAntoine Girardin
Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
1 shared publicationBaptiste Louveau
Solid Tumor Genomics Department Saint‐Louis Hospital Paris France
1 shared publicationBernard Cribier
Dermatopathology Unit, Clinique Dermatologique Hôpitaux Universitaires de Strasbourg Strasbourg France
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.
- 18 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Top Cited PapersOpen AccessImmune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.
- Open Access
- 8 March 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (10) , 897-902
Microsecretory adenocarcinoma of the skin, a novel type of sweat gland carcinoma: Report of three additional cases
Microsecretory adenocarcinoma (MSA) is a newly described salivary gland tumor harboring a characteristic balanced chromosomal translocation resulting in MEF2C::SS18 gene fusion. Six primary cutaneous MSA cases have been recently described. We report three additional cases confirming the relevance of this recently identified entity of primary cutaneous adnexal tumor. Three patients aged 53‐, 64‐ and 78‐year‐old were retrospectively diagnosed with MSA of the skin (MSAS) as consultation cases of the CARADERM (CAncers RAres DERMatologiques) national network. The clinical presentation was an indolent nodule on the upper extremities. There was no history of salivary gland tumor. Histopathologically, the tumors presented as dermal nodular proliferation with slightly infiltrative borders, composed of cribriform and microcystic structures with abundant myxoid intraluminal secretion embedded in a fibromyxoid stroma. They diffusely expressed cytokeratin 8 and SOX10, focally p63 and heterogeneously smooth muscle actin. All tumors harbored the MEF2C::SS18 gene fusion. A complete surgical excision was performed. No local recurrence or distant metastases were observed so far (follow‐up: 17, 38, and 45 months). MSAS is the cutaneous homologue of MSA of the salivary gland, a low‐grade adnexal neoplasm whose prognosis seems to be excellent once the complete removal of the tumor is assured.
- 8 March 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (10) , 897-902
Open AccessMicrosecretory adenocarcinoma of the skin, a novel type of sweat gland carcinoma: Report of three additional cases
Microsecretory adenocarcinoma (MSA) is a newly described salivary gland tumor harboring a characteristic balanced chromosomal translocation resulting in MEF2C::SS18 gene fusion. Six primary cutaneous MSA cases have been recently described. We report three additional cases confirming the relevance of this recently identified entity of primary cutaneous adnexal tumor. Three patients aged 53‐, 64‐ and 78‐year‐old were retrospectively diagnosed with MSA of the skin (MSAS) as consultation cases of the CARADERM (CAncers RAres DERMatologiques) national network. The clinical presentation was an indolent nodule on the upper extremities. There was no history of salivary gland tumor. Histopathologically, the tumors presented as dermal nodular proliferation with slightly infiltrative borders, composed of cribriform and microcystic structures with abundant myxoid intraluminal secretion embedded in a fibromyxoid stroma. They diffusely expressed cytokeratin 8 and SOX10, focally p63 and heterogeneously smooth muscle actin. All tumors harbored the MEF2C::SS18 gene fusion. A complete surgical excision was performed. No local recurrence or distant metastases were observed so far (follow‐up: 17, 38, and 45 months). MSAS is the cutaneous homologue of MSA of the salivary gland, a low‐grade adnexal neoplasm whose prognosis seems to be excellent once the complete removal of the tumor is assured.